which also leads me back to Surescreen. This was in the announcement last winter. What gives??
The supply agreement contains standard terms for an agreement of this nature and provides for a minimum commitment of 10 million Rhinomed swabs over a 24 month period with an option to renew. The agreement is exclusive in the Australian, New Zealand, Singapore and South Pacific region. Pricing remains commercial in confidence. SureScreen has indicated it will commence ordering swabs for inclusion in test kits this month. Investors should note that this arrangement has the potential to represent in excess of 160%+ of H1FY22 revenues of $3.75m and maintenance of exclusivity is conditional upon meeting the agreed minimum volume.
RNO Price at posting:
8.7¢ Sentiment: Hold Disclosure: Not Held
